GlaxoSmithKline ( ($GSK) ) has released its Q2 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors.

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage ...

CEO Emma Walmsley maintained that continued investment in the U.S. is a priority for the pharma to ensure its medicines for ...

British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, ...

GSK ( NYSE: GSK) CEO Emma Walmsley said on Wednesday that her company is in discussions with the Trump administration on how ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions in a report that ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

(Alliance News) - GSK PLC on Thursday said its Blenrep blood cancer treatment has been approved in Europe, as it awaits a final decision from the US regulator. The London-based pharmaceutical firm ...

A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.

Each year, 1·3 million people die from viral hepatitis, and mortality is increasing.1 This World Hepatitis Day, all stakeholders must break down the barriers to hepatitis elimination, including ending ...